Frexalimab Shows Strikingly Positive Results in Treatment of Relapsing Multiple Sclerosis
Frexalimab, a second-generation anti-CD40L antibody, has shown “strikingly positive” effects in treating relapsing multiple sclerosis (MS), significantly reducing disease activity without depleting B cells. The drug is a novel, second-generation monoclonal antibody designed to block the costimulatory CD40/CD40L cellular pathway, the mechanism of which is believed to potentially modify T-and B-cell activation and innate immune … Read more